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Abstract 
The review covers the current recommenda-
tions for Merkel cell carcinoma (MCC), with
detailed discussion of many controversies. The
2010 AJCC staging system is more in-line with
other skin malignancies although more com-
plicated to use.  The changes in staging system
over time make comparison of studies difficult.
A wide excision with margins of 2.5-3 cm is
generally recommended. Even for primary </=
1 cm, there is a significant risk of nodal and
distant  metastases  and  hence  sentinel  node
biopsy should be done if possible; otherwise
adjuvant radiotherapy to the primary and nodal
region should be given. Difficulties of setting
up trials owing to the rarity of the disease and
the mean age of the patient population result
in infrequent reports of adjuvant or concurrent
chemotherapy in the literature. The benefit, if
any, is not great from published studies so far.
However, there may be a subgroup of patients
with high-risk features, e.g. node-positive and
excellent performance status, for whom adju-
vant or concurrent chemotherapy may be con-
sidered. Since local recurrence and metastases
generally occur within 2 years of the initial
diagnosis,  patients  should  be  followed  more
frequently in the first 2 years. However delayed
recurrence can still occur in a small proportion
of patients and long-term follow-up by a spe-
cialist is recommended provided that the gen-
eral condition of the patient allows it. In sum-
mary, physician judgment in individual cases
of  MCC  is  advisable,  to  balance  the  risk  of
recurrence versus the complications of treat-
ment. 
Introduction
Merkel cell carcinoma (MCC) of the skin,
formerly  called  trabecular  carcinoma,  is  an
uncommon,  highly  malignant  primary  cuta-
neous  neuroendocrine  carcinoma  occurring
mostly in white, elderly patients.1 About 78% of
patients are older than 59 years. The tumor is
most often located in the head and neck region
(50.8%) or the extremities (33.7%). The aver-
age size is 29 mm at presentation. Clinically,
only a presumptive diagnosis of MCC can be
established. The definitive diagnosis is made
by  histology,  especially  immunohistological
methods (detection of intermediate filaments
and neuroendocrine markers).2
The incidence of MCC has been rising in
recent years and is more than the increased
incidence of cutaneous melanoma.3 More than
one-third of MCC patients will die from this
cancer, making it twice as lethal as melanoma.
Its incidence is markedly greater in immuno-
compromised  patients.  In  these  patients  we
often observe the highly aggressive and deadly
course of MCC. The link between tumorigene-
sis and immunosuppression is well known and
the  increased  prevalence  of  MCC  in  human
immunodeficiency virus carriers, organ trans-
plant recipients and in patients with hemato-
oncological neoplasias is well recognized.4-6  In
this  respect,  chronic  lymphocytic  leukemia
seems to be the most frequent neoplasia asso-
ciated  with  the  development  of  MCC.  Very
recently, a newly described virus, the Merkel
cell polyomavirus, was found in about 80% of
MCC tumor samples. The virus may constitute
the missing link between immunosuppression
and the development of MCC.7
Diagnosis of Merkel cell carcinoma 
The clinical diagnosis is made with the typ-
ical clinical presentation of a rapidly growing,
painless, firm, non-tender, shiny, bluish red,
intracutaneous nodule often of mean size 2.9
cm (the range can be from 0.5-5 cm) in diam-
eter.  Sometimes  it  can  take  the  form  of  a
plaque. The tumor is usually localized to sun
exposed areas of the head and neck, but does
also occur in extremities, trunk, genitalia and
the perianal region in a random distribution. 
Staging 
The  staging  system  of  MCC  has  changed
over the years. Readers are cautioned when
comparing  different  series  using  different
staging  systems.  Yiengpruksawan  et  al  pro-
posed the following classification derived from
their  experience  of  70  cases  treated  in
Memorial  Sloan-Kettering  Cancer  Center  in
1991 (Table 1).8
In 19999 and 2005,10 Allen updated the stag-
ing system using data from Memorial Sloan-
Kettering Cancer Center (Table 2).   
In 2010, the American Joint Committee on
Cancer (AJCC) Staging System11 first included
the staging system for MCC (Table 3).
The  staging  system  shown  in  Table  3  is
more  in-line  with  other  skin  malignancies
although more complicated to use. The litera-
ture  used  the  older  staging  system  making
comparison difficult with newer studies that
use this AJCC system in the future.
Management of Merkel cell carcinoma
Surgery
Surgery  is  the  mainstay  of  treatment  for
MCC  if  feasible.  Controversies  in  surgical
management  of  MCC  include  the  extent  of
required surgical margin, the role of sentinel
node biopsy (SNB) and node dissection. 
What  are  the  risk  factors  for  local  recur-
rence? Geopfert et al suggested that the poor
risk factors are primary lesion more than 1.5
cm, resection margin within 2 mm, and lym-
phatic permeation.12  Ott et al proposed an ade-
quate  resection  margin  of  at  least  2  cm  is
required from their experience in a series of
33  patients  treated  at  the  Massachusetts
General  Hospital.13 Yiengpruksawan  et  al
reported that local recurrence developed in 4 of
27 patients with margins ≤3 cm compared with
none of 11 patients with margins > 3 cm.5 A
wide excision with margins of 2.5-3 cm has
been recommended based on studies showing
a significant reduction in local recurrence rate
by increasing the margins from 1 to 3 cm.8,14-16
Despite claims of effectiveness of Mohs sur-
gery, RT is always given after Mohs surgery in
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University  of  Wisconsin.  Mohs  surgery  fol-
lowed  by  RT  is  particularly  useful  in  small
facial MCC owing to the better cosmetic out-
come.17 In a Mayo Clinic study, Mohs surgery
compares  favorably  with  standard  surgical
excision.18 Radiotherapy  after  Mohs  surgery
may further reduce persistent metastases, in-
transit and nodal disease.18
The necessity of elective nodal treatment is
another controversial topic in surgery. Opinion
varies  as  to  whether  small  MCC  has  a  low
enough risk of nodal metastases that elective
nodal surgery or RT can be avoided. Tumor size
>1 cm was found to be a poor prognostic factor
by Clark JR et al.19 Allen et al. found 2 cm to be
a significant cutoff for poor prognosis.10 In the
study by Allen et al.9out of 26 patients in which
SNB was performed, 5 had LN metastases and
out of these one had a tumor size </=1 cm. In
his follow-up paper in 2005, operative LN stag-
ing was performed in 71 patients with clinical-
ly negative nodes and a total of 16 patients
(23%) had positive nodes. Positive nodes were
discovered in 24% of patients with tumors <2
cm in diameter and in 20% of patients with
tumors  >2  cm  in  diameter  (P=0.71).10
Stawowy et al suggested that if the primary
tumor  is  larger  than  2  cm,  contains  10  or
greater mitoses per high-power field, demon-
strates  evidence  of  lymphatic  invasion  or  is
composed of the small cell variant, a partial
regional  node  dissection  is  recommended.20
Stokes et al. reported that MCC </= 1 cm are
unlikely to harbour nodal metastases.21 Only
2/54 patients (4%) with tumor size </= 1 cm
had clinical regional node metastases at diag-
nosis. None of the remaining 52 patients with
tumor size </= 1 cm and clinically negative
nodes were found to have pathological nodes
on surgical staging at the time of presentation.
However  we  have  combined  our  experience
with cases from the literature – 105 cases with
tumor </= 1 cm, 87 with tumor >1 to <2 cm
and 241 with tumor >/= 2 cm.22 We concluded
that for primary tumor with size </= 1 cm, a
significant  risk  of  nodal  and  distant  metas-
tases exists and therefore SNB should always
be  done  if  general  condition  of  the  patient
allows (Table 4).22 If not, adjuvant radiotherapy




In the literature, MCC has a good response
to  RT.  In  the  Peter  MacCallum  Cancer
Institute, a complete response of measurable
tumor was observed in 22 out of 23 sites (96%)
with 1 partial response (4%), i.e., an overall
response rate of 100%. There was only 1 recur-
rence in an irradiated site (after a low radia-
tion dose).23 
Even  for  distant  metastases,  palliative  RT
can  give  good  results.  A  case  of  MCC  with
proven brain metastasis and a solid choroidal
tumor responded well to RT and chemotherapy.
The patient was alive and neurologically intact
in follow-up assessment three years after diag-
nosis.24
Adjuvant radiotherapy
Recently, there is a debate on the role of
adjuvant RT. Most authors favor its use. In MD
Anderson Cancer Center, postoperative radio-
therapy has been recommended routinely.25,26
From the literature review of 1024 cases, adju-
vant RT was associated with a reduced risk of
local recurrence (P <0.00001).27 
The largest series is from the SEER data,
showing  that  the  median  survival  for  those
patients receiving adjuvant RT was 63 months
compared  with  45  months  for  those  treated
without adjuvant RT. The use of RT was associ-
ated  with  an  improved  survival  for  patients
with all sizes of tumors, but the improvement
with  RT  use  was  particularly  prominent  in
patients  with  primary  lesions  larger  than 
2 cm.28 
A combined series of 110 patients with head
and  neck  MCC  from  Princess  Margaret
Hospital of Toronto, Westmead Hospital, and
Royal Prince Alfred Hospital of Sydney showed
that combined surgery and RT improves both
loco-regional  control  and  disease-free  sur-
vival.29 17  patients  from  Royal  Prince  Alfred
Hospital in Sydney over a 7-year period (medi-
an follow-up 16 months) was reported in a sep-
arate  paper.30 There  were  9  patients  who
received adjuvant RT to the primary site, with-
out  any  in-field  recurrences;  and  8  who
received  RT  to  their  RLN  field,  with  only  2
developing RLN recurrences - both were SN
biopsy positive. The results suggest that SN
status may not be an accurate predictor of loco-
regional  recurrence  in  MCC.  However,  they
strongly  reinforce  previous  reports  that  RT,
both  locally  and  to  regional  nodes,  provides
effective in-field disease control. 
Similar striking work to show effectiveness
of RT to prevent local recurrence was found by
Meeuwissen:31 all  of  the  38  patients  treated
with surgery alone relapsed. The median time
to recurrence was 5.5 months. Ten of the 34
patients treated with surgery and RT relapsed.
The  median  time  to  recurrence  was  16.5
months. 
In  another  series,  local  control  could  be
achieved in all 5 patients irradiated immedi-
ately after surgical treatment of the primary
tumor.  In  contrast,  an  in-field  recurrence
occurred in 5 of 12 patients irradiated after
surgical  excision  of  relapsed  disease.32
Patients undergoing wide local excision, pro-
phylactic lymph node dissection, and adjuvant
RT  had  significantly  decreased  loco-regional
and distant recurrence rates and improved sur-
vival when compared with their counterparts.
Article
Table  1.  Merkel  cell  carcinoma  Staging
System, 1991.
T1 Tumor size 2 cm or less
T2 Greater than 2 cm in maximum diameter
Stage I   Local disease only 
Stage II  Positive regional nodes 
Stage III Systemic metastases
Table  2.  Merkel  cell  carcinoma  Staging
System, 1999, 2005.
Stage I Primary <2 cm
Stage II  Primary 2 cm or more
Stage III  Nodal disease
Stage IV  Systemic metastases 
Table  3.  Merkel  cell  carcinoma  Staging
System, 2010.
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor (e.g. 
nodal/metastatic presentation without 
associated primary)
Tis In situprimary tumor
T1 Less than or equal to 2 cm maximum tumor 
dimension
T2  Greater than 2 cm but not more than 5 cm 
maximum tumor dimension 
T3 Over 5 cm maximum tumor dimension 
T4  Primary tumor invades bone, muscle, fascia, 
or cartilage
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
cN0 Nodes negative by clinical exam 
(no pathologic node exam performed)
pN0 Nodes negative by pathologic exam 
N1 Metastasis in regional lymph node(s)
N1a Micrometastasis
N1b Macrometastasis
N2 In transit metastasis
Distant metastasis
M0 No distant metastasis
M1 Metastasis beyond regional lymph nodes
M1aMetastasis to skin, subcutaneous tissues 
or distant lymph nodes
M1bMetastasis to lung
M1cMetastasis to all other visceral sites
Anatomic stage/prognostic groups
Stage 0 Tis N0 M0
Stage IA T1  pN0 M0
Stage IB T1  cN0 M0
Stage IIA T2/T3  pN0 M0
Stage IIB T2/T3  cN0 M0
Stage IIC T4  N0 M0
Stage IIIA Any T  N1a M0
Stage IIIB Any T  N1b/N2 M0
Stage IV Any T  Any N M1[Rare Tumors 2011; 3:e23] [page 73]
Adjuvant  chemotherapy  did  not  diminish
recurrence  rates  nor  improve  survival.  Both
loco-regional and distant recurrences signifi-
cantly decreased survival.33
One of the most notable contrary findings is
from  the  series  of  the  Memorial  Sloan
Kettering Cancer Center. In their study adju-
vant RT did not offer any survival benefit, nor
improved  local  control  (P=0.76).10,34
Unfortunately, in this study, only 17% of the
251 patients received adjuvant radiation thera-
py,  and  this  small  number  of  patients  may
reflect an underpowered study. One may won-
der surgeons from tertiary care centers may
have more experience and whether the conclu-
sion can be generalized to small community
centers.
The  reader  should  note  that  the  recom-
mended radiation doses are higher than those
used in the older literature. For gross positive
resection  margins,  unresectable  primary  or
nodes, RT dose of 60-66Gy/30-33 fractions is
recommended  in  the  NCCN  guidelines.  Our
overall summary is shown in Figure 1.35
Systemic therapy
Controversies  exist  regarding  the  role  of
chemotherapy  in  terms  of  primary  concomi-
tant  chemo-radiation,36 and  adjuvant
chemotherapy after local treatment.  
The  Trans-Tasman  Radiation  Oncology
Group  TROG  9607  enrolled  53  patients  with
high risk features including: recurrence after
initial therapy, involved nodes, primary tumor
size greater than 1 cm, gross residual disease
Article
Table 4. Treatment and outcome of 132 patients from a combined series of the institutions of our authors, with different primary tumor sizes
(7 patients with unknown size of primary and 6 patients with no primary are excluded in this table). Lower panel adds 288 cases from the lit-
erature14 to the current series, so total number of patients analyzed was 433. (Total %) below indicates the incidence of nodal or distant dis-
ease(s) at presentation + later recurrence on follow-up.
Combined series N Surgery to Radiotherapy to  LR LN(total %) DM(total %) Any recurrence
Primary size Primary   Node Primary    Node
≤1 cm 47 46 4a 2 12b 8(17%) 5+3(17%) 0+8(17%) 14(30%)
>1 to <2 cm 33 32 5a 20 11c 4(12%) 4+9(39%) 0+6(18%) 17(52%)
≥2 cm 52d 51 9e 19 12f 17(33%) 8+23(60%) 5+16(40%) 40(77%)
c2test P values 0.152 0.002 0.054 0.007
Literature  N Surgery to Radiotherapy to  LR LN(total %) DM(total %) Any recurrence
cases added  Primary   Node Primary    Node
Primary size
≤1 cm 105 91 4g 28 18g 24(23%) 9+21(29%) 0+20(19%) 44(42%)h
>1 to <2 cm 87 68 12i 16 9i 23(26%) 11+23(39%) 0+20(23%) 55(61%)j
≥2 cm 241 186 28k 39 20k 61(25%) 50+72(51%) 7+72(33%) 160(71%)l
c2test P values 0.898 0.015 0.049 0.022
a5 patients had nodes at presentation, of which 4 had surgery to nodal area in addition to primary tumor as well; bonly 2 of the stage III patients had nodal radiotherapy; conly 3 of the 4 stage III patients had nodal radiotherapy
after wide local excision of primary and node dissection; dat presentation, there are 8 stage III and 5 stage IV patients; DM, total distant metastases at diagnosis and on follow-up; e6 of the 8 stage III patients had node dissec-
tion in addition to wide local excision of primary tumor;  3 of the 8 stage III patients had nodal radiotherapy after nodal dissection and 1 of the stage III patient had therapeutic nodal radiotherapy after local excision of primary;
1/5 of the stage IV had palliative nodal radiotherapy; LN, total nodal metastases at diagnosis and on follow-up;g,i,k2, 3 and 7 had both nodal surgery and radiotherapy respectively; h,j,l1, 5 and 15 had unknown recurrence status
respectively. LR, local recurrence; N, patient number.  
Figure 1. Summary recommendations. LND, lymph node dissection; N0, node negative;
N+, node positive; RT, radiotherapy; SN, sentinel node; SNB, sentinel node biopsy; WLE,
wide local excision; -, negative.[page 74] [Rare Tumors 2011; 3:e23]
after surgery, or occult primary with nodes.37
Treatment regimen included irradiation of the
primary site and nodes to a dose of 50 Gy in 25
fractions over 5 weeks and synchronous carbo-
platin  (area  under  the  curve,  4.5)  together
with intravenous etoposide 80 mg/m2 days 1 to
3 in weeks 1, 4, 7, and 10. High levels of loco-
regional  control  and  survival  have  been
achieved with the addition of chemotherapy to
radiation treatment for high-risk MCC of the
skin. However, a later study found that com-
pared  to  historical  control,  the  addition  of
chemotherapy  did  not  significantly  increase
survival.38 One would expect treatment results
in later era to be better than historical control,
the fact that there is no significant increase in
survival makes us to conclude therefore, the
benefit of concomitant chemotherapy, if any,
would not be very great. This coupled with the
occurrence in the elderly patients makes adju-
vant  chemotherapy  infrequently  reported  in
the literature. However, there may be a sub-
group of patients with high-risk features, e.g.
node-positive and excellent general condition,
for whom adjuvant chemotherapy may still be
considered.
Much of the literature on chemotherapy for
MCC used old drugs. Past conclusions on the
role of chemotherapy in the initial, adjuvant or
salvage  settings  should  be  revisited  in  the
future with newer agents, including molecular
target agents. As to date, there are no major
studies on molecular target agents in MCC yet.
There are occasional reports of cure from
treatment  with  tumor  necrosis  factor  and
interferon.39 A  substantial  reduction  in
immunosuppressive  drugs  in    immunosup-
pressed  patients  by  switching  to  mTOR
inhibitors appears to substantially improve the
prognosis in a series with miscellaneous skin
neoplasms, although this may not always work
in others.40-43We await more reports on MCC in
the future. 
In the future, prophylaxis with vaccination
against Merkel cell polyomavirus will hopefully
be possible in high-risk patients, as well as
therapeutic  usage  of  antisense  oligonu-
cleotides or microRNAs, even eventually, com-
plete MCC eradication by affecting the tumor
suppressor gene Atonal homolog 1 expression.3
Post-treatment follow-up
Local recurrence and metastases generally
occur within two years from the initial diagno-
sis.44 Therefore  patients  should  be  followed
more frequently in the first two years: every 1-
3 months for the first year, every 3-6 months
for  the  second  year  and  annually  thereafter
with physical examination and imaging if clin-
ically indicated.35 Delayed recurrence can still
occur  in  a  small  proportion  of  patients  and
long-term follow-up by specialist is preferred,
unless the general condition of the patient or
social circumstances precludes this.
Conclusion
Due to rarity of MCC, clinical experience is
limited. The literature contains single institu-
tional  studies  of  tertiary  centers.  Readers
should exercise discretion in applying these
experiences  to  smaller  centers  with  less
expertise. The present review has highlighted
areas of confusion in the literature and sum-
marized  the  current  recommendations  in  a
flow chart.
References
1. Albores-Saavedra  J,  Batich  K,  Chable-
Montero  F,  et  al.  Merkel  cell  carcinoma
demographics,  morphology,  and  survival
based on 3870 cases: a population based
study. J Cutan Pathol 2010;37:20-7. 
2. Meyer  Pannwitt  U,  Kummerfeldt  K,
Boubaris P, Caselitz J. Merkel cell tumor or
neuroendocrine  skin  carcinoma.
Langenbecks Arch Chir 1997;382:349 58. 
3. Krejcí K, Zadrazil J, Tichý T, et al. Merkel
cell  skin  carcinoma.  Klin  Onkol
2010;23:210-7.
4. Bensaleh H, Perney P, Dereure O, et al.
Merkel cell carcinoma in a liver transplant
patient. Am J Clin Dermatol 2007;8:239-41.
5. Engels  EA,  Frisch  M,  Goedert  JJ,  et  al.
Merkel cell carcinoma and HIV infection.
Lancet 2002;359:497-8.
6. Heath,  M,  Jaimes,  N,  Lemos,  B,  et  al.
Clinical characteristics of Merkel cell car-
cinoma at diagnosis in 195 patients: the
AEIOU  features.  J  Am  Acad  Dermatol
2008;58:375-81.
7. Tadmor T, Aviv A, Polliack A. Merkel cell
carcinoma, chronic lymphocytic leukemia
and  other  lymphoproliferative  disorders:
an old bond with possible new viral ties.
Ann Oncol 2011;22:250-6. 
8. Yiengpruksawan A, Coit DG, Thaler HT, et
al. Merkel cell carcinoma. Prognosis and
management. Arch Surg 1991;126:1514-9.
9. Allen  PJ,  Zhang  ZF,  Coit  DG.  Surgical
Management  of  Merkel  Cell  Carcinoma.
Ann Surg 1999;229:97-105. 
10. Allen  PJ,  Bowne  WB,  Jaques  DP,  et  al.
Merkel  cell  carcinoma:  prognosis  and
treatment of patients from a single institu-
tion. J Clin Oncol 2005;23:2300-9.
11. American  Joint  Committee  on  Cancer.
AJCC  cancer  staging  handbook.  Merkel
cell carcinoma. New York: Springer; 2010.
p. 377-86.
12. Goepfert H, Remmler D, Silva E, Wheeler
B. Merkel cell carcinoma (endocrine carci-
noma of the skin) of the head and neck.
Arch Otolaryngol 1984;110:707-12. 
13. Ott  MJ,  Tanabe  KK,  Gadd  MA,  et  al.
Multimodality management of Merkel cell
carcinoma. Arch Surg 1999;134:388-92.
14. Ratner D, Nelson BR, Brown MD, Johnson
TM.  Merkel  cell  carcinoma.  J  Am  Acad
Dermatrol 1993;29:143-56.
15. Hitchcock CL, Bland KI, Laney RG, et al.
Neuroendocrine (Merkel cell) carcinoma
of the skin. Its natural history, diagnosis,
and treatment. Ann Surg 1988;207:201 7. 
16. Shaw JH, Rumball E. Merkel cell tumor:
clinical  behaviour  and  treatment.  Br  J
Surg 1991;78:138-42.
17. Snow SN, Larson PO, Hardy S, et al. Merkel
cell  carcinoma  of  the  skin  and  mucosa:
report of 12 cutaneous cases with 2 cases
arising from the nasal mucosa. Dermatol
Surg 2001;27:165-70. 
18. O'Connor WJ, Roenigk RK, Brodland DG.
Merkel  cell  carcinoma.  Comparison  of
Mohs micrographic surgery and wide exci-
sion in eighty-six patients. Dermatol Surg
1997;23:929-33. 
19. Clark  JR,  Veness  MJ,  Gilbert  R,  et  al.
Merkel  cell  carcinoma  of  the  head  and
neck: Is adjuvant radiotherapy necessary?
Head and Neck 2007;29:249-57.
20. Stawowy LM, Krull EA, Maeda K. Merkel
cell  carcinoma:  a  challenge.  J  Dermatol
Surg Oncol 1986;12:443 7.
21. Stokes JB, Lamond KG, Dengel LT, et al.
Patients  with  Merkel  Cell  carcinoma
tumors < 1.0 cm in diameter are unlikely
to harbor regional lymph node metastasis.
J Clin Oncol 2009;27:3772-7.
22. Tai  P, Yu E, Assouline A, Lian JD, et al.
Management  of  Merkel  cell  carcinoma
with emphasis on small primary tumors –
a case series and review of the current lit-
erature. J Drugs Dermatol 2010;9:105-10.
23. Pacella J, Ashby M, Ainslie J, et al. The role
of radiotherapy in the management of pri-
mary  cutaneous  neuroendocrine  tumors
(Merkel  cell  or  trabecular  carcinoma):
experience at the Peter MacCallum Cancer
Institute  (Melbourne,  Australia).  Int  J
Radiat Oncol Biol Phys 1988;14:1077-84.
24. Alexander E 3rd, Rossitch E Jr, Small K, et
al. Merkel cell carcinoma. Long term sur-
vival in a patient with proven brain metas-
tasis  and  presumed  choroid  metastasis.
Clin Neurol Neurosurg 1989;91:317-20.
25. Morrison  WH,  Garden  AS,  Ang  KK.
Radiation therapy for nonmelanoma skin
carcinomas. Clin Plast Surg 1997;24:719-
29.
26. Morrison WH, Peters LJ, Silva EG, et al.
The essential role of radiation therapy in
securing  locoregional  control  of  Merkel
cell  carcinoma.  Int  J  Radiat  Oncol  Biol
Phys 1990;19:583-91. 
27. Medina-Franco H, Urist MM, Fiveash J, et
al. Multimodality treatment of Merkel cell
Article[Rare Tumors 2011; 3:e23] [page 75]
carcinoma:  case  series  and  literature
review  of  1024  cases.  Ann  Surg  Oncol
2001;8:204-8.
28. Mojica P, Smith D, Ellenhorn JD. Adjuvant
radiation  therapy  is  associated  with
improved survival in Merkel cell carcino-
ma of the skin. J Clin Oncol 2007;25:1043-
7.
29. Clark  JR,  Veness  MJ,  Gilbert  R,  et  al.
Merkel  cell  carcinoma  of  the  head  and
neck: is adjuvant radiotherapy necessary?
Head Neck 2007;29:249-57.
30. Warner  RE,  Quinn  MJ,  Hruby  G,  et  al.
Management of merkel cell carcinoma: the
roles  of  lymphoscintigraphy,  sentinel
lymph node biopsy and adjuvant radiother-
apy. Ann Surg Oncol 2008;15:2509-18. 
31. Meeuwissen JA, Bourne RG, Kearsley JH.
The importance of postoperative radiation
therapy in the treatment of Merkel cell car-
cinoma.  Int  J  Radiat  Oncol  Biol  Phys
1995;31:325 31.
32. Bischof M, van Kampen M, Huber P, et al.
Merkel cell carcinoma: the role of radia-
tion  therapy  in  general  management.
Strahlenther Onkol 1999;175:611-5.
33. Kokoska ER, Kokoska MS, Collins BT, et al.
Early aggressive treatment for Merkel cell
carcinoma improves outcome. Am J Surg
1997;174:688-93.
34. Housman  DM,  Decker  RH,  Wilson  LD.
Regarding  adjuvant  radiation  therapy  in
Merkel cell carcinoma: selection bias and
its affect on overall survival. J Clin Oncol
2007;25:4503-4.
35. National Comprehensive Cancer Network.
Available form: www.nccn.org. 
36. Prosser J, Bhatt N, Coleman T, Jackson L.
Case report of periocular Merkel Cell carci-
noma  treated  with  primary  concomitant
chemotherapy and radiation, and review of
the  literature  regarding  its  use.
Laryngoscope 2010;120:S177.
37. Poulsen  M,  Rischin  D,  Walpole  E,  et  al.
High-risk  Merkel  cell  carcinoma  of  the
skin  treated  with  synchronous  carbo-
platin/etoposide  and  radiation:  a  Trans-
Tasman Radiation Oncology Group Study--
TROG 96:07. J Clin Oncol 2003;21:4371-6.
38. Poulsen  MG,  Rischin  D,  Porter  I,  et  al.
Does  chemotherapy  improve  survival  in
high-risk stage I and II Merkel cell carcino-
ma of the skin? Int J Radiat Oncol Biol
Phys 2006;64:114-9.
39. Hata Y, Matsuka K, Ito O, et al. Two cases
of Merkel cell carcinoma cured by intratu-
mor  injection  of  natural  human  tumor
necrosis  factor.  Plast  Reconstr  Surg
1997;99:547 53.
40. Leiter U, Garbe C. Skin cancer in organ
transplant  patients.  Epidemiology  and
management.  Hautarzt 2010;61:207-13.
41. Boratyńska M, Watorek E, Smolska D, et
al. Anticancer effect of sirolimus in renal
allograft  recipients  with  de  novo  malig-
nancies. Transplant Proc 2007;39:2736-9.
42. Kurnatowska I, Zawiasa A, Narbutt J, et al.
Merkel cell carcinoma in a kidney trans-
plant patient: Case report and update on
management. Ann Transplant 2010;15:66-
70.
43. Krejčí K, Tichý T, Horák P, et al. Merkel cell
carcinoma of the gluteal region with ipsi-
lateral metastasis into the pancreatic graft
of  a  patient  after  combined  kidney-pan-
creas transplantation. Onkologie 2010;33:
520-4.
44. Henness S, Vereecken P. Management of
Merkel  tumours:  an  evidence-based
review. Curr Opin Oncol 2008,20:280-6.
Article